Miejsce antagonistów receptora dla aldosteronu w leczeniu niewydolności serca Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2011
Słowa kluczowe:
niewydolność serca, antagoniści aldosteronu, zalecenia
##plugins.themes.bootstrap3.article.main##
Abstrakt
W artykule omówiono rolę antagonistów aldosteronu w leczeniu niewydolności serca. Leki z tej grupy są znane od ponad 50 lat. Ich zastosowanie w leczeniu chorób układu sercowo-naczyniowego uzasadniają zarówno badania nad układem renina-angiotensyna, jak i nad samymi lekami. Antagoniści aldosteronu są obecnie stosowani głównie w leczeniu nadciśnienia tętniczego i niewydolności serca. Są to jednak leki rzadko wykorzystywane. Ich znaczenie w leczeniu niewydolności serca pokazują badania RALES, EPHESUS i EMPHASIS-HF. Zgodnie z wynikami tych badań antagoniści aldosteronu powinni być brani pod uwagę u chorych we wszystkich okresach skurczowej niewydolności serca, niezależnie od etiologii choroby. Leki są rekomendowane w leczeniu niewydolności serca przez liczne towarzystwa naukowe.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
Lewandowski , J., & Jędrusik , P. (2011). Miejsce antagonistów receptora dla aldosteronu w leczeniu niewydolności serca . Kardiologia W Praktyce, 5(4), 157-163. Pobrano z https://www.journalsmededu.pl/index.php/kwp/article/view/1591
Numer
Dział
Artykuły
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Cowie M.R., Mosterad A., Wood D.A. et al.: The epidemiology of heart failure. Eur. Heart J. 1997, 18: 208-225.
2. Kannel W., Ho K., Thom T.: Changing epidemiological features of cardiac failure. Br. Heart J. 1994, 72(supl. 2): S3-S9.
3. Rywik S.L., Wagrowska H., Broda G. et al.: Heart failure in patients seeking medical help at out-patients clinics. Part I. General characteristics. Eur. J. Heart Fail. 2000, 2: 413-421.
4. Cowie M.R., Wood D.A., Coats A.J.S. et al.: Survival of patients with a new diagnosis of heart failure: A population-based study. Heart 2002, 83: 505-510.
5. Steward S., MacIntyre K., Hole D.J.: More „malignant” than cancer? 5-years survival following a first admission with heart failure. Eur. J. Heart Fail. 2001, 3: 315-322.
6. Hobbs F.D.: Management of heart failure: evidence versus practice. Does current prescribing provide optimal treatment for heart failure patients? Br. J. Gen. Pract. 2000, 50(458): 735-42.
7. Moscavitch S.D., Garcia J.L., Rosa L.F. et al.: Are the heart failure guidelines being implemented in primary care? Rev. Port. Cardiol. 2009, 28(6): 683-96.
8. Calvert M.J., Shankar A., McManus R.J. et al.: Evaluation of the management of heart failure in primary care. Fam. Pract. 2009, 26(2): 145-53.
9. Albert N.M., Yancy C.W., Liang L. et al.: Use of aldosterone antagonists in heart failure. JAMA 2009, 302(15): 1658-65.
10. Hyla-Klekot L., Pulcer B., Kokot F.: Układ renina-angiotensyna-aldosteron – nowe aspekty patogenetyczne i lecznicze. Aldosteron – ważny induktor szlaków patogenetycznych uszkadzających układ sercowo-naczyniowy i nerki. Arterial Hypertension 2007, (7)4: 357-363.
11. Gomez Sanchez E.P.: What is the role of the central nervous system in mineralocorticoid hypertension? Am. J. Hypertens. 1991, 4: 374-381.
12. Lombes M., Alfaidy N., Eugene E. et al.: Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. Circulation 1995, 92: 175-182.
13. Takeda Y., Miyamori I., Inaba S. et al.: Vascular aldosterone in genetically hypertensive rats. Hypertension 1997, 29: 45-48.
14. Connell J.M., Davies E.: The new biology of aldosterone. J. Endocrinol. 2005, 186: 1-20.
15. Rocha R., Stier C.T. Jr, Kifor I. et al.: Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000, 141: 3871-8.
16. Hollenberg N.K.: Aldosterone in the development and progression of renal injury. Kidney Int. 2004, 4: 1-9. 17. Farquharson C.A., Struthers A.D.: Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone induced vasculopathy. Clin. Sci. (Lond) 2002, 103: 425-31.
18. Park J.B., Schiffrin E.L.: Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1. Am. J. Hypertens. 2002, 15: 164-9.10.
19. Fiebeler A., Muller D., Shagdarsuren E. et al.: Aldosterone, mineralocorticoid receptors, and vascular inflammation. Curr. Opin. Nephrol. Hypertens. 2007, 16: 134-142.
20. Pitt B., Zannad F., Remme W.J. et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. NEJM 1999, 341: 709-17.
21. Pitt B., Remme W., Zannad F. et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Eng. J. Med. 2003, 348(14): 1309-1321.
22. Pitt B., White H., Nicolau J. et al.: Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J. Am. Coll. Cardiol. 2005, 46: 425-431.
23. Zannad F., Adamopoulos C., Fay R. et al.: How early should eplerenone be initiated in acute myocardial infarction complicated by heart failure? An analysis of early vs late initiation in the EPHESUS trial. Eur. Heart J. 2007, 28: 52.
24. Zannad F., McMurray J.J., Krum H. et al., EMPHASIS-HF Study Group: Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 2011, 6, 364(1): 11-21
25. [online: www.topcatstudy.com].
26. Edelmann F., Schmidt A.G., Gelbrich G. et al.: Rationale and design of the ‘aldosterone receptor blockade in diastolic heart failure’ trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). Eur. J. Heart Fail. 2010, 12: 874-82.
27. The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 2008.
28. 2007 Writing Committee Members: 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction: a Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011, 123: 2022-2060.
29. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur. Heart J. 2008, 29: 2909-2945.
30. Antman E.M., Hand M., Armstrong P.W. et al.: 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. J. Am. Coll. Cardiol. 2008, 51: 210-47.
31. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. European Heart Journal 2008, 29: 2388-2442.
32. 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009, 119: 1977-2016.
2. Kannel W., Ho K., Thom T.: Changing epidemiological features of cardiac failure. Br. Heart J. 1994, 72(supl. 2): S3-S9.
3. Rywik S.L., Wagrowska H., Broda G. et al.: Heart failure in patients seeking medical help at out-patients clinics. Part I. General characteristics. Eur. J. Heart Fail. 2000, 2: 413-421.
4. Cowie M.R., Wood D.A., Coats A.J.S. et al.: Survival of patients with a new diagnosis of heart failure: A population-based study. Heart 2002, 83: 505-510.
5. Steward S., MacIntyre K., Hole D.J.: More „malignant” than cancer? 5-years survival following a first admission with heart failure. Eur. J. Heart Fail. 2001, 3: 315-322.
6. Hobbs F.D.: Management of heart failure: evidence versus practice. Does current prescribing provide optimal treatment for heart failure patients? Br. J. Gen. Pract. 2000, 50(458): 735-42.
7. Moscavitch S.D., Garcia J.L., Rosa L.F. et al.: Are the heart failure guidelines being implemented in primary care? Rev. Port. Cardiol. 2009, 28(6): 683-96.
8. Calvert M.J., Shankar A., McManus R.J. et al.: Evaluation of the management of heart failure in primary care. Fam. Pract. 2009, 26(2): 145-53.
9. Albert N.M., Yancy C.W., Liang L. et al.: Use of aldosterone antagonists in heart failure. JAMA 2009, 302(15): 1658-65.
10. Hyla-Klekot L., Pulcer B., Kokot F.: Układ renina-angiotensyna-aldosteron – nowe aspekty patogenetyczne i lecznicze. Aldosteron – ważny induktor szlaków patogenetycznych uszkadzających układ sercowo-naczyniowy i nerki. Arterial Hypertension 2007, (7)4: 357-363.
11. Gomez Sanchez E.P.: What is the role of the central nervous system in mineralocorticoid hypertension? Am. J. Hypertens. 1991, 4: 374-381.
12. Lombes M., Alfaidy N., Eugene E. et al.: Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. Circulation 1995, 92: 175-182.
13. Takeda Y., Miyamori I., Inaba S. et al.: Vascular aldosterone in genetically hypertensive rats. Hypertension 1997, 29: 45-48.
14. Connell J.M., Davies E.: The new biology of aldosterone. J. Endocrinol. 2005, 186: 1-20.
15. Rocha R., Stier C.T. Jr, Kifor I. et al.: Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000, 141: 3871-8.
16. Hollenberg N.K.: Aldosterone in the development and progression of renal injury. Kidney Int. 2004, 4: 1-9. 17. Farquharson C.A., Struthers A.D.: Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone induced vasculopathy. Clin. Sci. (Lond) 2002, 103: 425-31.
18. Park J.B., Schiffrin E.L.: Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1. Am. J. Hypertens. 2002, 15: 164-9.10.
19. Fiebeler A., Muller D., Shagdarsuren E. et al.: Aldosterone, mineralocorticoid receptors, and vascular inflammation. Curr. Opin. Nephrol. Hypertens. 2007, 16: 134-142.
20. Pitt B., Zannad F., Remme W.J. et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. NEJM 1999, 341: 709-17.
21. Pitt B., Remme W., Zannad F. et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Eng. J. Med. 2003, 348(14): 1309-1321.
22. Pitt B., White H., Nicolau J. et al.: Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J. Am. Coll. Cardiol. 2005, 46: 425-431.
23. Zannad F., Adamopoulos C., Fay R. et al.: How early should eplerenone be initiated in acute myocardial infarction complicated by heart failure? An analysis of early vs late initiation in the EPHESUS trial. Eur. Heart J. 2007, 28: 52.
24. Zannad F., McMurray J.J., Krum H. et al., EMPHASIS-HF Study Group: Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 2011, 6, 364(1): 11-21
25. [online: www.topcatstudy.com].
26. Edelmann F., Schmidt A.G., Gelbrich G. et al.: Rationale and design of the ‘aldosterone receptor blockade in diastolic heart failure’ trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF). Eur. J. Heart Fail. 2010, 12: 874-82.
27. The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 2008.
28. 2007 Writing Committee Members: 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction: a Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011, 123: 2022-2060.
29. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur. Heart J. 2008, 29: 2909-2945.
30. Antman E.M., Hand M., Armstrong P.W. et al.: 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. J. Am. Coll. Cardiol. 2008, 51: 210-47.
31. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. European Heart Journal 2008, 29: 2388-2442.
32. 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009, 119: 1977-2016.